A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

NCT04987970 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension and Dyslipidemia

Interventions

DRUG: CKD-386(2)
DRUG: D013, D326, D337

Sponsor

Chong Kun Dang Pharmaceutical